综合孟德尔随机化和实验验证揭示了初级胆管胆道炎中新型可用药物的标
Yinling Li1, Huanhuan Xie2, Zhenjie Zhuang2
1Department of Translational Medicine Center, Hangzhou Normal University Affiliated Hospital, Hangzhou, Zhejiang, China; Institute of Hepatology and Metabolic Diseases, Hangzhou Normal University, Hangzhou, Zhejiang, China; Department of School of Life Sciences, Zhejiang University of Traditional Chinese Medicine, Hangzhou, Zhejiang 310053, China.
European journal of pharmacology
|March 12, 2026
概括
这项研究确定CD58和IL7R是原发性胆道胆道炎 (PBC) 的关键遗传标. 这些发现支持对这种渐进的自身免疫性肝病开发新疗法.
科学领域:
- 基因组学和免疫学
- 药物发现和开发 药物发现和开发
背景情况:
- 初级胆管胆道炎 (PBC) 是一种渐进的自身免疫性肝脏疾病,具有显著的未满足的治疗需求.
- 目前的治疗方法,如ursodeoxycholic acid (UDCA),对于大量的患者是无效的.
- 对于PBC管理,迫切需要新的治疗目标.
研究的目的:
- 通过使用多omics方法识别初级胆汁胆道炎 (PBC) 的新型,可用药物的遗传标.
- 阐明PBC病原体的生物学机制,并确定潜在的治疗化合物.
- 在临床前模型和人体样本中验证已识别的目标和化合物.
主要方法:
- 全基因组门德尔随机化 (MR) 框架整合 cis-eQTL,pQTL 和 PBC GWAS 数据.
- 贝叶斯局部化和全现象MR (Phe-MR) 用于因果推断和非目标效应评估.
- 蛋白与蛋白相互作用 (PPI) 网络,转录基因分析,药物重定位 (DSigDB),分子对接,以及体内/体外验证.
主要成果:
- 确定了14个与PBC风险有因果关系的可用药物基因,CD58和IL7R已被确认为Tier-1目标.
- 已证明CD58和IL7R调节免疫突触形成和T细胞平衡,在PBC中具有肝脏过度表达.
- 通过分子对接优先考虑PHA-00665752和monorden;PHA-00665752在减弱胆固醇定位方面显示出有效性.
结论:
- 确定CD58和IL7R作为PBC的机制验证的治疗点.
- 提供了一个从因果基因组学到PBC药物发现的翻译框架.
- 证明已识别的化合物对胆固醇损伤的保护作用,为未来的PBC治疗开发提供信息.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:16Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However, frequent irregular...
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:18Drug Delivery: Enteral Route
The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
Drugs in...
Drugs in...